



SYNAGIS (RSV) INDEPENDENCE BLUE CROSS ENROLLMENT FORM

Today's Date:			
Needed By:			
Last undata 0 17 2019			







Enroll via phone at: 800.906.7798 Enroll via fax at: 877.381.3806 E-prescribing NCPDP: 3982902 NPI: 1639103823

Enroll via phone at: 888.203.7973 Enroll via fax at: 888.203.7980

E-prescribing NCPDP: 1079638 NPI: 1598762015 www.commcarepharmacy.com

Patient Demographics:(Please provide the following or attach demographics sheet)		Provider Office: (Please provide as much information as possible)			
Patient Name:		Prescriber's Name: Group/Hospital:			
Address:		Specialty:License#:			
		Address:			
Last four digits of SS#: Date of Birtl		NPI:			
Gender:_Allergies:Height:	Weight:	Phone: Fax:	Office Contact		
Gender: _Allergies: Height: Weight: Phone: Fax: Office Contact Insurance Information: (Please copy and attach the front and back of the patient's primary and/or secondary insurance cards)					
Medication Delivery to: (choose one) Patient Address Always to Physician's Office First fill to Physician's Office, refills to Patient Address					
Medical Criteria (Please attach clinical documentation for all diagnoses below)					
1. Bronchiolitis RSV Hospitalization? Yes No					
2. Diagnosis of Chronic Lung Diseases (CLD) of prematurity? \(\text{Yes} \) \(\text{No} \) \(\text{ICD-10:} \)					
Oxygen: Concentration: Dates:					
□Supporting Clinical Documents are attached for Oxygen Use					
□Bronchodilator Dates:// □Corticosteroids Dates:// □Diuretics Dates://					
3. Diagnosis of Hemodynamically Significant Congenital Heart Disease? Yes No ICD-10:					
Please include letter from Cardiologist. Patient has the following conditions:					
□Diagnosis of Moderate-Severe Pulmonary Hypertension					
☐Medications for CHF (list): Date last received://					
Recent Surgical Procedure Requiring Cardiopulmonary Bypass					
☐Yes ☐No – If yes, an additional post-operative dose of palivizumab may be medically necessary					
4. Diagnosis of Cystic Fibrosis with one of the following risk factors? Yes No ICD-10:					
□Clinical Evidence of CLD □Nutritional Compromise □Weight for length less than 10 th percentile					
☐Manifestations of severe lung disease (prev	vious hospitalization for pul	monary exacerbation in the first year o	f life or abnormalities on chest		
radiography or chest computed tomography	that persist when stable)				
6. Diagnosis of Congenital Abnormalities of the airway and 12 months of age or less? Yes No ICD-10:					
7. Neuromuscular condition that compromises handling of respiratory secretions and 12 months of age or less? Yes No ICD-10:					
Patient's Gestational Age: weeksdays	Rx		Expected Date of First/Next Injection:		
ICD-10:	□SYNAGIS (palivizuma	ab) 50 mg and/or 100 mg Vials	//		
Birth Weight:g/ kg / lbs	•	IM One Time per Month	Previous Injections? ☐Yes ☐No		
Current Weight: g/ kg / lbs		·	Dates:		
Date Recorded:	Dispense Quantity:				
NICU History	Refills Through:	_//	☐Parent/Caregiver contact:		
□Yes □No			- <u>-</u>		
NICU Name:	Other Rx		☐Parent/Caregiver has been		
Please Attach the NICU Discharge Summary			contacted, and we have been		
Was there a NICU Dose Administered?			granted permission to contact.		
□Yes □No Dates: / /	<u> </u>				
Unless otherwise noted this prescription authorizes Acro and Commcare to dispense & share information between each other to optimize care delivery. Check here to restrict to \Box Acro \Box Commcare					
Physician Signature: DAW (Dispense as Written) Date:					
Patient Support Programs: I authorize Acro Pharmaceutical Services and Commcare Specialty Pharmacy to enroll me in company-assisted patient support program, corresponding with my prescribed therapy for purposes of receiving additional services such as, but not limited to injection training. I further authorize the release to communicate to the corresponding manufacturer the minimum necessary information about my health condition and prescription(s) to: coordinate the delivery of products and services available through the patient assistance program, aggregate de-identified data for market analysis or other commercial purposes, and provide educational information regarding therapies. I understand that I may refuse to sign this authorization and that my refusal will not affect my ability to obtain treatment from the pharmacy. However, I will not be enrolled in the service program					
listed above. A copy of this authorization will be utilized with the same effectiveness as an original. Ancillary supplies provided as needed for administration.					
*Patient Signature: (required for participation)	Date:	☐ Please select if you would like	the patient enrolled in a Manufacturer's Assistance Program		
CONFIDENTIALITY NOTICE: If you are not the intended recipient or the person responsible for delivering it to the intended recipient, you are hereby notified that you are not authorized to read, print, retain, copy or disseminate this message, any part of it, or any attachments. This facsimile message may contain information that is confidential, privileged, proprietary, or otherwise legally exempt from disclosure or use. Any disclosure or use of this facsimile message by any person other than the intended recipient or person responsible for delivering it to the intended recipient may constitute a Federal criminal offense punishable by imprisonment up to 10 years or fines up to \$250,000. If you have received this message in entertor, please destroy this message and any accompanying attachments in their entirety without reading the content and notify the sender immediately by telephone of the inadvertent transmission, by calling collect if located outside the calling area. There is no intent on the part of the sender to waive any right or privilege that may be attached to this communication. Thank you for your cooperation. *This prescription is valid only if transmitted by means of a facsimile machine from the authorized prescriber.					